A Phase III, Multicentre, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicentre, randomized, placebo-controlled, double-blind study to
evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who
are at high risk of disease recurrence following nephrectomy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society